Full Text View
Tabular View
No Study Results Posted
Related Studies
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
This study has suspended participant recruitment.
Study NCT00031083   Information provided by Biogen Idec

First Received on February 20, 2002.   Last Updated on June 7, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Glioblastoma Multiforme
Anaplastic Astrocytoma
Oligoastrocytoma, Mixed
Gliosarcoma
Additional conditions recognized in this trial
Astrocytoma
Glioblastoma
Glioma
Oligodendroglioma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Interventions listed in this trial
Interferon-beta
Additional drug interventions recognized in this trial
Interferons
More general drug interventions related to this trial
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Biogen Idec


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services